



# MEMORANDUM

To: All Regional Medical Laboratory, Inc. (RML) Clients

From: Regional Medical Laboratory, Inc.  
 Ryan Hatley, MHA, C(ASCP)<sup>CM</sup>, Manager of Chemistry  
 Caitlin Schein, MD, Clinical Director, RML Central Laboratory Chemistry and LC/MS

Date: May 14, 2018

**Subject: Updated Immunoassay Reference Ranges**

---

Regional Medical Laboratory is pleased to announce full implementation of the Abbott i System for immunoassay testing on May 22, 2018. The Abbott i System will bring workflow efficiencies and improved assay performance compared with existing processes while maintaining high sensitivity and specificity. This new platform utilizes chemiluminescent microparticle immunoassay (CMIA) technology that is not susceptible to biotin interference. As a result of this methodology change, several reference ranges will be updated. A list of impacted tests is included below. Please review patient results obtained after May 22, 2018, for noted updates to reference ranges. Updated reference ranges will be charted with each patient result.

AFP	Cortisol	Free T3	Hepatitis B Surface Ag	LH	Testosterone
β-hCG	C-Peptide	Free T4	Hepatitis B Surface Ag Conf	Progesterone	Total T3
BNP	Cyclosporine	FSH	Hepatitis C Ab	Prolactin	Total T4
CA 125	Digoxin	Hepatitis A IgG	HIV Ag/Ab	PSA, Total	Troponin I
CA 15-3	DHEA-S	Hepatitis A IgM	Homocysteine	PSA, Free	TSH
CA 19-9	Estradiol	Hepatitis B Core Total Ab	IgE	SHBG	T-Uptake
CEA	Ferritin	Hepatitis B Core IgM	Insulin	Syphilis	Vitamin B-12
CK-MB	Folate	Hepatitis B Surface Ab	Intact PTH	Tacrolimus	Vitamin D

In-house testing of **Hepatitis A Total Antibody** will be discontinued in favor of **Hepatitis A IgG**, and in-house testing of **CA27.29** will be discontinued in favor of **CA 15-3**.

Please contact Ryan Hatley or Dr. Caitlin Schein at 918-744-2553 with questions regarding this